Clinical data were coded by two investigators (RMH, LHN). Score sheets with the relevant variables for each patient were sent in random order to a panel of experts (JFTG, APM, JBPS) who independently assigned a 'Reye score' to each case using the predetermined protocol (appendix). The scores ranged from a maximum of 25 (for a case manifesting all the features of 'classical' Reye's syndrome) to a minimum of 1.
Score sheets differing by 4 points between any two of the three experts (indicating maximum variation in the opinion of the panel of the information in the free text section) were returned to be rescored. The averaged final Reye score for each case was entered on the original record file in the surveillance scheme database.
Those cases in whom the admission diagnosis of Reye's syndrome (leading to a report of a suspected case as requested by the surveillance scheme methodology) had subsequently been revised by the reporting clinician were not scored. This was because for most there was little accompanying clinical information other than the final diagnosis. Their ages and admission dates were, however, usually reported.
ANALYSIS
Analysis initially carried out in Epi-Info explored the relationship between mean Reye score and the following explanatory variables: age; preadmission medication; onset period (defined as before or after June 1986); year and season of onset.
A preliminary univariate analysis examined the Reye score in its continuous form, whereas for the main analysis the scores were grouped into three categories (1-12; 13-16; 17+), such that there were approximately equal numbers of cases in each category. This was to observe possible differences in low, intermediate, and high scoring cases. The explanatory variables were also grouped where appropriate (table) .
Differences in mean Reye score within each of the explanatory variables were tested using analysis of variance (ANOVA) or KruskalWallis where applicable. Multivariable analysis (to assess the independent effect of each on the score) was performed in GLIM using a Poisson log-linear model for each score category. Two way interactions between variables were assessed to establish whether the effect of any one changed the effect that other variables had on the Reye score. The results of preliminary univariate analysis of the association between mean Reye score and the explanatory variables are shown in the table. Overall, the differences in mean Reye score between categories of preadmission medication (no drug, aspirin, other drug, not known) were highly significant (p<0-0001). A significantly higher mean Reye score was observed for cases with a reported exposure to aspirin compared with that (15-3) for exposure to other drugs (p=0003) and that (13 7) for no drug (p<0-001). Ten per cent (7/68), 10% (7/74), and 37% (38/102) of cases scoring 1-12, 13-16, and 17 + respectively had a reported history of aspirin exposure before June 1986. The corresponding figures after the warning were 0, 6% (2/32), and 14% (3/21).
As expected from the data shown in the figure, a significantly higher mean Reye score was also observed for cases occurring before Examination ofinteractions between the variables showed only one: onset period and season. This suggested that the seasonal distribution of cases differed before, compared with after, the aspirin warning. However, this evidence was not strong enough to justify adjusting for these differences in the model (p=0 06). Thus, after allowing for confounding and interaction, these analyses suggested that there were three independent determinants of Reye score: age; preadmission medication; and onset before or after mid-1986.
Discussion
In this study we aimed to determine whether there was a change in the pattern of Reye's syndrome between 1982 and 1990, and if so to explore reasons for that change by innovative use of existing surveillance data.
We devised a scoring system using objective criteria to allocate each patient a place on a spectrum of disease ranging from 'non-classical' (low scorers) to 'classical' (high scorers) Reye's syndrome. The latter resembled patients reported to the United States Reye's syndrome surveillance scheme in the 1970s and early 1980s and those recruited to the case-control studies in that country.5 [11] [12] [13] [14] [15] [16] [17] The intermediate and low scorers may have included some cases of Reye's syndrome, but we surmised that these patients were more likely to have a range of undiagnosed 'Reyelike' disorders. 1-3 [27] [28] [29] Two other studies retrospectively reviewed the medical records of patients with an admission4 or discharge28 diagnosis of 'Reye's syndrome' to assess the likelihood that some of them had been misdiagnosed. Both studies, like ours, used an expert panel. Although one specified a number of criteria to classify cases as 'certain', 'probable', 'unlikely', or 'excluded',28 neither used a scoring system.
The expert panels in the two other studies concluded that one third4 and three quarters28 of their cases definitely or probably did not have Reye's syndrome, and that 30% and 28% respectively could only be assigned as 'uncertain' or 'probable'. In our study, the wide distribution of scores suggested that reported cases of Reye's syndrome were a clinically heterogeneous group. This heterogeneity emphasises the need to regard 'Reye's syndrome' as consisting of a number of conditions, including inherited metabolic disorders, and to consider suspected patients as having a 'Reye-like disorder' until alternative diagnoses have been excluded.2 If our scoring system is a valid predictor of 'Reye' versus 'Reye-like' then the patients with revised diagnoses should have had low scores. Unfortunately, the lack of systematically collected clinical information in this group, inherent in the surveillance system methodology, precluded such an analysis. It could, however, easily be undertaken by referral centres with large series of such cases.
Multivariable analysis indicated that our high scoring cases tended to be older. This is consistent with the epidemiological picture of Reye's syndrome in the United States in the 1970s and early 1980s. Furthermore each of the other studies found that their 'definite' and 'probable' cases were significantly older than those categorised as 'uncertain' and 'definitely not' Reye's syndrome.4 28 One explanation for the observed association between age and Reye score groups is that the 'non-classical', low scoring cases may have had unrecognised inherited Reye-like metabolic disorders. These involve absence or low activity of individual enzymes in key steps in the urea cycle or fatty acid oxidation pathways. Although We observed a decline in absolute numbers of cases within each of the score groups in the second 41,2 year study period compared to the first. However, the downward trends in the low and intermediate score groups (by 41% and 57O/% respectively) were substantially smaller than that in the high scorers (79%). The decline in low and intermediate scorers is consistent with our suggestion that these groups contained patients with undiagnosed Reye-like inherited metabolic and other disorders and with speculation that, in recent years, such patients have been the subject of earlier and more precise laboratory diagnosis and may not, therefore, be reported as Reye's syndrome.2426
This alternative explanation for the falling incidence of the syndrome (as against the effect of aspirin warnings) does not, however, explain the significantly greater decline in the subset of patients who most resemble classical Reye's syndrome. If this notion were correct, our score categories should either have declined at equal rates, or low scoring cases should have shown the greater decline. Furthermore, detailed investigation of classical cases of Reye's syndrome has not revealed any inherited metabolic disorders (Glasgow JFT, unpublished data, and29) and by virtue of their older age they are the least likely group to have such disorders. It was noteworthy too that the numbers of revised diagnosis cases were almost identical in each study period even though the reporting criteria did not change between 1982 and 1990.
We conclude that, within the overall decline in reported cases of Reye's syndrome, there was a significantly greater reduction in high scoring ('classical') cases, compared to lower scoring patients, after June 1986. The former were also older and more likely to have had preadmission aspirin. We believe that these observations support our hypothesis that, If information in one of these categories is not detailed here then it was not provided in the original case description.
within the heterogeneity of conditions encompassed by the diagnostic criteria of 'Reye's syndrome', there is a subset which is aetiologically associated with aspirin ingestion. The findings of a recent French study support our argument: a series of patients admitted with Reyelike illnesses was extensively investigated for inherited metabolic disorders.30 Those with negative findings were significantly more likely to have had aspirin than those in whom such a disorder was found.
Our scoring system could be useful if included in a continuing epidemiological surveillance system for Reye's syndrome. It would enable early detection of an increase in cases with high scores, indicating a possible need to re-emphasise aspirin warnings, especially during an influenza epidemic.
Although we have surmised that the lower the score the more likely is an inherited metabolic disorder, these conditions must always be included in the differential diagnosis of all 'Reye-like' illnesses. This is especially important in very young patients, but ideally those at all ages should be intensively investigated.l 2630 Preadmission medication exposure should not influence diagnosis in either direction. Until its aetiopathogenesis is fully elucidated, it would be unwise to assume that all cases, even of 'classical' Reye's syndrome, were aspirin associated.
